BIOMAT Database Logo BIOMAT Database Logo

Distinction between liver neoplasm promoting and syncarcinogenic effects demonstrated by exposure to phenobarbital or diethylnitrosamine either before or after N-2-fluorenylacetamide. 1984

G M Williams, and K Furuya

The effect on the liver carcinogenicity in rats of sequential administration of either phenobarbital (PB) or diethylnitrosamine (DEN) given either before or after N-2-fluorenylacetamide (FAA) was studied. DEN given in the drinking water either before or after dietary FAA enhanced liver carcinogenicity over that produced by FAA alone. In contrast, dietary PB produced enhancement only when given after FAA. Thus, the effects of DEN summate with those of FAA, whereas PB produces a promoting, but not syncarcinogenic, effect. The usefulness of reverse sequence protocols for distinguishing between initiation-promotion and syncarcinogenesis by sequentially administered chemicals is demonstrated.

UI MeSH Term Description Entries
D008099 Liver A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances. Livers
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D008297 Male Males
D009602 Nitrosamines A class of compounds that contain a -NH2 and a -NO radical. Many members of this group have carcinogenic and mutagenic properties. Nitrosamine
D010634 Phenobarbital A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. Phenemal,Phenobarbitone,Phenylbarbital,Gardenal,Hysteps,Luminal,Phenobarbital Sodium,Phenobarbital, Monosodium Salt,Phenylethylbarbituric Acid,Acid, Phenylethylbarbituric,Monosodium Salt Phenobarbital,Sodium, Phenobarbital
D011230 Precancerous Conditions Pathological conditions that tend eventually to become malignant. Preneoplastic Conditions,Condition, Preneoplastic,Conditions, Preneoplastic,Preneoplastic Condition,Condition, Precancerous,Conditions, Precancerous,Precancerous Condition
D011916 Rats, Inbred F344 An inbred strain of rat that is used for general BIOMEDICAL RESEARCH purposes. Fischer Rats,Rats, Inbred CDF,Rats, Inbred Fischer 344,Rats, F344,Rats, Inbred Fisher 344,CDF Rat, Inbred,CDF Rats, Inbred,F344 Rat,F344 Rat, Inbred,F344 Rats,F344 Rats, Inbred,Inbred CDF Rat,Inbred CDF Rats,Inbred F344 Rat,Inbred F344 Rats,Rat, F344,Rat, Inbred CDF,Rat, Inbred F344,Rats, Fischer
D002273 Carcinogens Substances that increase the risk of NEOPLASMS in humans or animals. Both genotoxic chemicals, which affect DNA directly, and nongenotoxic chemicals, which induce neoplasms by other mechanism, are included. Carcinogen,Oncogen,Oncogens,Tumor Initiator,Tumor Initiators,Tumor Promoter,Tumor Promoters,Initiator, Tumor,Initiators, Tumor,Promoter, Tumor,Promoters, Tumor
D004052 Diethylnitrosamine A nitrosamine derivative with alkylating, carcinogenic, and mutagenic properties. Nitrosodiethylamine,N-Nitrosodiethylamine,N Nitrosodiethylamine
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug

Related Publications

G M Williams, and K Furuya
Induction of hyperplastic liver nodules in hepatectomized rats treated with 3'-methyl-4-dimethylaminoazobenzene, benzo[a]pyrene or phenobarbital before or after exposure to N-2-fluorenylacetamide.
April 1982, Gan,
G M Williams, and K Furuya
Modifications of hepatic microsomal 9-oxidation of N-2-fluorenylacetamide in response to gonadectomy and treatment of rats with phenobarbital or diethylnitrosamine.
April 1989, Xenobiotica; the fate of foreign compounds in biological systems,
G M Williams, and K Furuya
Alterations of bioelectric potential in primary hepatocellular carcinomas induced by N-2-fluorenylacetamide or diethylnitrosamine.
January 1982, Cancer biochemistry biophysics,
G M Williams, and K Furuya
Effects of carbon tetrachloride and azathioprine on diethylnitrosamine and N-2-fluorenylacetamide-induced hyperplastic liver nodule and hepatocellular carcinoma.
December 1984, Acta medica Okayama,
G M Williams, and K Furuya
Alteration of hepatocytes by subcarcinogenic exposure to n-2-fluorenylacetamide.
July 1975, Cancer research,
G M Williams, and K Furuya
Enhancement of diethylnitrosamine hepatocarcinogenesis in rats by exposure to polychlorinated biphenyls or phenobarbital.
September 1976, Cancer letters,
G M Williams, and K Furuya
Detection of N-(deoxyguanosin-8-yl)-2-fluorenamine in DNA of peritoneal serosa and liver after intraperitoneal exposure of rats to N-hydroxy-N-2-fluorenylbenzamide or N-hydroxy-N-2-fluorenylacetamide.
December 1994, Carcinogenesis,
G M Williams, and K Furuya
Lack of rapid initiating, promoting or sequential syncarcinogenic effects of di(2-ethylhexyl)phthalate in rat liver carcinogenesis.
July 1987, Carcinogenesis,
G M Williams, and K Furuya
Mechanisms of the inhibitory action of p-hydroxyacetanilide on carcinogenesis by N-2-fluorenylacetamide or N-hydroxy-N-2-fluorenylacetamide.
April 1976, Journal of the National Cancer Institute,
G M Williams, and K Furuya
Hepatic cell loss and proliferation induced by N-2-fluorenylacetamide, diethylnitrosamine, and aflatoxin B1 in relation to hepatoma induction.
August 1977, British journal of cancer,
Copied contents to your clipboard!